| Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. | |
| | |
MedLine Citation:
|
PMID: 20580987 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND & AIMS: Albumin dialysis using molecular adsorbent recirculating system (MARS) is a new procedure for treating resistant pruritus from cholestasis, but it is usually published as a case report or a short series. Therefore, we analyzed patients with resistant pruritus treated with MARS from three centers, to assess the changes on pruritus and the indices of cholestasis. METHODS: Twenty patients (12 female, mean age: 51+/-3.4 years) with chronic cholestatic liver disease or chronic liver-graft rejection were evaluated. The severity of pruritus was assessed using a visual analogue scale (VAS) before and after treatment, and 30 days thereafter. Liver tests, including total bilirubin, alkaline phosphatase, gamma-glutamyl-transferase, cholesterol, triglycerides, and total bile acid were also determined, as well as the number of sessions and the coupled procedure (dialysis or perfusion). RESULTS: Albumin dialysis resulted in a decrease of pruritus (VAS: from 70.2+/-4.8 to 20.1+/-4.2, p<0.001), which partially resumed after 30 days (38.7+/-6.6). VAS decreased by 72% immediately after treatment and by 51% after 1 month. Pruritus decreased in all but one patient. MARS resulted in a significant bile acid decrease of 41% after treatment and by 37% after 1 month. The effect of MARS on pruritus and markers of cholestasis was similar in patients with different diseases and was independent of the coupled procedure. The improvement of pruritus in individuals was positive in 75% of patients. No major adverse effects were observed. CONCLUSIONS: Albumin dialysis using MARS is an effective procedure for managing resistant pruritus in most patients with chronic cholestasis and graft rejection. |
| | |
Authors:
|
Albert Parés; Manuel Herrera; Juan Avilés; Miquel Sanz; Antoni Mas |
Related Documents
:
|
3906227 - Effects of acetate and bicarbonate dialysate in stable chronic dialysis patients. 8151747 - Correlative factors of left ventricular hypertrophy in end-stage renal disease. 16105067 - Parameters derived by ultrasonic myocardial characterization in dialysis patients are a... 16847207 - Cutaneous calcification in patients with end-stage renal disease: a regulated process a... 21960047 - Evaluation of skin thickness lesions in patients with lyme disease measured by modified... 16702447 - Review of the abdominal manifestations of cystic fibrosis in the adult patient. |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't Date: 2010-05-07 |
Journal Detail:
|
Title: Journal of hepatology Volume: 53 ISSN: 0168-8278 ISO Abbreviation: J. Hepatol. Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-07-06 Completed Date: 2010-11-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8503886 Medline TA: J Hepatol Country: England |
Other Details:
|
Languages: eng Pagination: 307-12 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. |
Affiliation:
|
Liver Unit, Hospital Clinic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain. pares@ub.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Albumins
/
therapeutic use* Bile Acids and Salts / blood Cholestasis / blood, complications*, physiopathology Chronic Disease Dialysis Solutions / therapeutic use* Female Graft Rejection / blood, complications, physiopathology Hemofiltration / methods* Humans Liver Function Tests Liver Transplantation Male Middle Aged Pain Measurement Pruritus / etiology, therapy* Renal Dialysis / methods* Retrospective Studies Severity of Illness Index Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Albumins; 0/Bile Acids and Salts; 0/Dialysis Solutions |
| Comments/Corrections | |
Comment In:
|
J Hepatol. 2010 Aug;53(2):228-9
[PMID:
20494469
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The use of Lactobacillus brevis PS1 to in vitro inhibit the outgrowth of Fusarium culmorum and other...
Next Document: Integrating science and business models of sustainability for environmentally-challenging industries...